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ABSTRACT    ENGLISH 
The overall aim of this thesis was to investigate epidemiological and health economic aspects 
of dementia and drug use in older people, through economic modelling and analyses of 
population-based studies. The major findings from the separate studies are summarized 
below. 
Study I We aimed to investigate whether dementia was associated with higher drug costs in 
4,108 participants aged ≥ 60 years from the Swedish National Study on Aging and Care in 
Kungsholmen and Nordanstig (SNAC-K and SNAC-N). Overall, the average crude cost of 
drug use was 6,147 SEK per year for people with dementia and 3,810 SEK per year for 
people without dementia. The cost of nervous system drugs was more than five times higher 
in persons with dementia than without. However, the higher crude costs for drug use in 
people with dementia were confounded by comorbidities and residential setting. In fact, the 
strongest drug cost driver was comorbidity followed by residential setting. 
Study II We aimed to investigate inappropriate drug use (IDU) and risk of hospitalizations 
and mortality in older persons and in persons with dementia and to also estimate the costs of 
IDU-related hospitalizations. In this study, based on data from SNAC-K and SNAC-N, the 
National Patient Register and the Cause of Death Register, we used logistic and Cox 
regression models to analyse associations between IDU, hospitalizations and mortality in the 
whole study population and in the subpopulation of persons with dementia. We found a 
higher risk of hospitalization (adjusted OR=1.46; 95% CI 1.18-1.81) and mortality (adjusted 
HR=1.15; 95% CI 1.01-1.31) in the whole study population and with hospitalization 
(adjusted OR=1.88; 95% CI 1.03-3.43) in the subpopulation of persons with dementia, after 
adjustment for confounding factors. There was also a tendency for higher costs for 
hospitalizations with IDU than without IDU, although not statistically significant.  
Study III We aimed to describe the costs of an incident cohort of persons with dementia 
through simulation modelling. With input from epidemiological data, the Markov model 
estimated approximately 24,000 incident cases of dementia in Sweden in 2005. The incident 
cohort was run in the model for ten cycles of one year each. State specific costs were used 
and defined by the Clinical Dementia Rating scale. Results of the simulation showed that the 
total costs of the cohort were 27.7 billion SEK. The average annual cost of one person with 
dementia was 269,558 SEK. The severe state of dementia accounted for the largest 
proportion of costs for incident dementia cases. Costs of drugs in dementia only accounted 
for about 2% of the costs in the model. The main cost driver was institutional care, even for 
mild dementia. 
Study IV We aimed to introduce a hypothetical economic model of a disease modifying 
treatment (DMT) for Alzheimer’s disease (AD). We created a Markov model built on 
Swedish conditions with two arms; one representing the hypothetical treatment and the other 
arm representing no treatment. States and progression of the disease were defined with Mini 
Mental State Examination. Epidemiological data of incidence, prevalence and costs of mild 
cognitive impairment (MCI), studies of conversion from MCI to AD and official statistics 
were used as input in the model. The incremental cost effectiveness ratio was 293,002 
SEK/Quality Adjusted Life Year. The treated persons showed increased survival (8.7 years) 
versus the non-treated persons (7.8 years). With a societal willingness to pay of 600,000 
SEK, the hypothetical treatment can be considered as cost effective. The main reasons for the 
higher costs with DMT were the costs of DMT itself and the prolonged survival with DMT. 
Conclusion: The observed higher crude drug costs in dementia were confounded by 
comorbidities and residential setting. We also found that IDU was associated with an 
increased risk of hospitalization and mortality among older persons. This underlines the need 
for cautious prescribing to elderly patients. However, further studies are needed to investigate 
the association between IDU and costs for hospitalizations. 
The highest accumulated costs in dementia occur in severe dementia and the major cost 
driver is institutionalization, even in mild dementia. Drugs, on the other hand, constitute only 
a minor part of the total costs. Our study of a hypothetical DMT showed that DMT in AD is 
projected as not being cost saving if the treatment prolongs survival. Still, if a societal 
willingness-to pay level of 600,000 SEK is adopted, the treatment can be considered as cost 
effective. 
  
  
 
SAMMANFATTNING   SVENSKA 
Det övergripande syftet med denna avhandling var att undersöka epidemiologiska och 
hälsoekonomiska aspekter av demenssjukdom och läkemedelsanvändning hos äldre personer, 
genom ekonomisk modellering och analyser av populationsbaserade studier. De viktigaste 
resultaten från de separata studierna sammanfattas nedan. 
Studie I Vi undersökte om demenssjukdom var associerad med högre läkemedelskostnader 
hos 4108 personer i åldern ≥ 60 år som deltog i den svenska nationella studien om åldrande 
och vård på Kungsholmen och i Nordanstig (SNAC-K och SNAC-N). I genomsnitt var den 
totala årliga kostnaden för läkemedelsanvändning 6147 kr för personer med demenssjukdom 
och 3810 kr för dem utan demenssjukdom. Kostnaden för läkemedel med påverkan på 
nervsystemet var mer än fem gånger högre hos dem med demenssjukdom jämfört med dem 
utan demenssjukdom. Dock var de ojusterade, högre kostnaderna för läkemedelsanvändning 
hos personer med demenssjukdom orsakade av samsjuklighet och boendesituation. I själva 
verket var den starkaste kostnadsdrivaren samsjuklighet följt av boendesituation (dvs. att bo i 
särskilt boende). 
Studie II Vi undersökte olämplig läkemedelsanvändning, risken för sjukhusinläggningar och 
mortalitet hos äldre personer och personer med demenssjukdom. Dessutom beräknades 
kostnaderna för sjukhusinläggningar relaterade till olämplig läkemedelsanvändning. I denna 
studie, baserad på data från SNAC-K och SNAC-N, patientregistret och dödsorsaksregistret, 
använde vi logistisk och Cox regressionsanalys för att undersöka sambandet mellan olämplig 
läkemedelsanvändning, risken för sjukhusinläggningar och mortalitet i hela 
studiepopulationen och i subpopulationen med demenssjukdom. Vi fann en högre risk för 
sjukhusinläggning (justerad oddskvot = 1,46; 95 % konfidensintervall 1,18–1,81) och 
mortalitet (justerad Hazard kvot = 1,15; 95 % konfidensintervall 1,01–1,31) i hela 
studiepopulationen samt för sjukhusinläggning (justerad oddskvot = 1,88; 95 % 
konfidensintervall 1,03–3,43) i subpopulationen med demenssjukdom, efter justering för 
bakgrundsfaktorer. Det fanns också en tendens för att olämplig läkemedelsanvändning ledde 
till ökade kostnader för sjukhusinläggningar (dock inte statistiskt signifikant). 
Studie III Vi ämnade beskriva kostnaderna för en simulerad kohort bestående av 
nyinsjuknade personer med demenssjukdom genom ekonomisk simulering. Med data om 
kostnader och antal insjuknade från epidemiologiska källor och statistik från officiella källor, 
användes en Markovmodell i tio cykler bestående av ett år vardera med 24 000 hypotetiskt, 
nyinsjuknade personer med demenssjukdom i Sverige år 2005. Stadiespecifika kostnader 
användes och definierades med hjälp av Clinical Dementia Rating scale. Resultaten av 
simuleringen visade att de totala kostnaderna för kohorten var 27.7 miljarder kronor. Den 
genomsnittliga årskostnaden för en person med demenssjukdom var 269 558 kr. Svår demens 
stod för den största andelen av kostnaderna vid demenssjukdom. Kostnader för läkemedel vid 
demenssjukdom stod för endast cirka 2% av kostnaderna i modellen. Den huvudsakliga 
kostnadsdrivaren var institutionsboende, även vid mild demens. 
Studie IV Vi utvecklade en hypotetisk, ekonomisk modell för en sjukdomsmodifierande 
behandling vid Alzheimers sjukdom. Vi skapade en Markovmodell som bygger på svenska 
förhållanden med två armar där den ena representerar den hypotetiska sjukdomsmodifierande 
behandlingen och den andra representerar vård utan sådan behandling. Sjukdomsgrad och 
progression i sjukdomen definierades med hjälp av stadieindelning utifrån Mini Mental State 
Examination. Epidemiologiska data avseende nyinsjuknade, prevalens och kostnader för mild 
kognitiv svikt, studier av konvertering från mild kognitiv svikt till Alzheimers sjukdom och 
officiell statistik användes som data i modellen. Den inkrementella 
kostnadseffektivitetskvoten var 293 000 kr/vunnet kvalitetsjusterat levnadsår. De behandlade 
personerna hade en förlängd överlevnad (8,7 år) jämfört med de icke behandlade personerna 
(7,8 år). Med en samhällelig betalningsvilja på 600 000 kronor/ kvalitetsjusterat levnadsår, 
kan den hypotetiska sjukdomsmodifierande behandlingen betraktas som kostnadseffektiv. De 
främsta orsakerna till de högre kostnaderna med den sjukdomsmodifierande behandlingen var 
kostnaderna för behandlingen själv och för förlängd överlevnad. 
Slutsats: De observerade, ojusterade högre kostnaderna för läkemedelsanvändning hos 
personer med demenssjukdom var i själva verket orsakade av samsjuklighet och 
boendesituation. Vi fann också att olämplig läkemedelsanvändning var associerad med en 
ökad risk för sjukhusinläggningar och mortalitet bland äldre personer. Detta understryker 
behovet av varsam förskrivning av läkemedel till äldre patienter. Sambandet mellan olämplig 
läkemedelsanvändning och kostnader för sjukhusinläggningar behöver dock undersökas i fler 
studier. 
De högsta ackumulerade kostnaderna för demenssjukdom förekom vid svår demens och den 
främsta kostnadsdrivaren var institutionsboende, även vid mild demens. Läkemedel utgjorde 
endast en mindre andel av de totala kostnaderna. Vår studie av en hypotetisk 
sjukdomsmodifierande behandling vid Alzheimers sjukdom visade att denna behandling inte 
kan förväntas bli kostnadsbesparande om behandlingen förlänger överlevnaden. Men om en 
samhällelig betalningsvilja på 600 000 kronor antas, kan en sådan behandling betraktas som 
kostnadseffektiv.  
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1 INTRODUCTION 
1.1 AGING POPULATIONS 
Global aging is projected to increase at the end of this century as birth rates decline and life 
expectancy increases (1). The age structure of the population shifts when the median age and 
the proportion of older people increase worldwide (2, 3). Figure 1 shows that the total 
population worldwide is expected to increase in the future and the largest increase is expected 
among persons aged 60 years and over. It is apparent that the proportion of people aged over 
60 years is expected to grow markedly until 2050.  
 
  
Figure 1. World population from 1980 to 2050 in different age groups. Source: 
http://esa.un.org/unpd/popdev/AgingProfiles2013/default.aspx (4). 
In absolute numbers, more than 860 million inhabitants in the world were over the age of 60 
years in 2010, which corresponds to a three-fold increase since 1950. Today, the highest 
proportion of older persons reside on the European continent, but trajectories of the world 
population estimates that in 2050 almost 80% of the older people in the world will live in 
developing countries (1).  
It is often argued that the increase in population aging is driven by increasing longevity and 
this is indeed an important factor, but there are also other explanations (1). Decreasing 
fertility rates alter the age structure of the population and lead to higher median ages and 
demographic aging (5). This phenomenon is known as the demographic transition (6). This 
transition is characterized by a change from high levels to low levels of both fertility and 
mortality rates.   
A higher proportion of people reaching old age is an achievement of society. However, health 
care utilization and other needs of the elderly population are likely to increase as a 
consequence of this achievement. Figure 2 shows the proportion of people in the ages 60+ 
years and 80+ years in 1980 and in 2050 in the world. The forecasts in Figure 2 shows a two-
 2 
fold increase in the proportion of people aged 60 years and over between the years 1980 and 
2050. 
 
 
Figure 2. The share of older persons by age and sex. Source: 
http://esa.un.org/unpd/popdev/AgingProfiles2013/default.aspx (4) 
The demands on health care systems will depend upon whether the added years of life are 
healthy or whether they are years with morbidity and disability; thus increasing needs for care 
(7-10). It is also difficult to predict how patterns of older peoples’ demand on care will 
change in the future (11). 
As people live longer, many will suffer from age-related disorders, such as dementia, and 
many will use several drugs for their multiple conditions. These are major challenges for the 
society. Therefore, this thesis explored epidemiological and health economic aspects of 
dementia and drug use, through economic modelling and analyses of population-based 
studies. 
1.2 DEMENTIA AND MILD COGNITIVE IMPAIRMENT 
1.2.1 Dementia 
Dementia is a syndrome with progressive deterioration in several cognitive domains that 
interfere with activities of daily living (ADL) (12). The cognitive deficits include mainly 
memory impairment and deterioration of at least one other cognitive domain, such as aphasia, 
agnosia or disturbances in executive functioning (13). Alzheimer’s disease (AD) is the most 
common dementia disorder and accounts for 60 – 70% of dementia cases (14, 15). There is 
currently no available cure for dementia, only symptom relieving drugs (16). 
The worldwide occurrence of dementia was estimated to 36 million affected persons in 2010 
(17). However, evidence of declining incidence is now emerging in high income countries 
around the world (18-22). Still, the number of people with dementia is expected to increase 
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over the next decades as the older population grows larger also in developing countries (1). It 
has been predicted that in 2030, 66 million people worldwide will be affected by dementia 
and in 2050 as many as 115 million (23).  
Dementia is a disorder that affects many levels of society. Firstly, the individual suffers from 
impairments in cognition and functioning as well as impaired quality of life and shortened 
life expectancy (24, 25). Secondly, the relatives suffer from gradually losing a family 
member and in return receive a high care burden for the affected person. Indeed, the need for 
informal care increases when the dementia progresses with deteriorating cognition and 
functioning (26). Thirdly, dementia has a strong economic impact on the society. Care for 
persons with dementia is very costly and resource-demanding for both the formal and 
informal sector (17). 
1.2.2 Mild cognitive impairment  
Mild cognitive impairment (MCI) is a heterogeneous concept that includes self or informant- 
reported cognitive complaint, objective cognitive impairment, but being independent in ADL 
and not demented (27-29). There are suggestions of several subtypes of MCI; amnestic MCI 
and non-amnestic MCI where the discriminator is performance on neuropsychological tests 
of episodic memory. Amnestic MCI is characterized by poor episodic memory whereas non-
amnestic MCI is characterized by poor performance in other domains, such as executive 
function, language and visuospatial ability (27).  
The diagnosis of MCI is often difficult to determine, but use of biomarkers for AD may be 
helpful when setting a MCI diagnosis that is related to AD (30, 31). People with MCI are 
shown to convert to AD at a much higher rate than the general elderly population (28). In a 
review, the average conversion rate to dementia was about 10%, but showed great variability 
(32). However, not all people with MCI convert to dementia. 
1.2.3 Diagnostics and treatment of dementia 
Swedish national guidelines on care for dementia patients state that an investigation should be 
performed if cognitive decline is present and the underlying cause of the symptoms is not 
known (33). The investigation is divided into basic and expanded investigation. The basic 
investigation is based on patient history, simple cognitive tests, computed tomography scan 
and assessment of function (34). The expanded investigation includes, besides the basic 
investigation, neuropsychologic testing procedures, imaging techniques like positron 
emission tomography (PET) and magnetic resonance imaging (MRI) and the use of 
biomarkers in cerebro-spinal fluid (35-40). The underlying credential is that pathological 
changes in the brain may be present before the functional decline is observed (41-45).  
Besides symptomatic treatment (46), drugs that are developed today for treatment of AD and 
other dementias aim to influence the progression of the disease and are, thus, disease 
 4 
modifying treatments (DMT) (47-49). For AD, the main discussion is whether the underlying 
mechanism is related to pathological amyloid or tau aggregation (50-56). 
1.3  PHARMACOEPIDEMIOLOGY 
Pharmacoepidemiology is epidemiologic methods applied to studies of drug use in 
populations. It may be defined as the study of the utilization and effects of drugs in large 
numbers of people (57). Concepts from both epidemiology and pharmacology are used to 
build a bridge between the two. 
This thesis is based on geriatric pharmacoepidemiology, which is becoming increasingly 
important as global aging proceeds (58, 59). Older people use more drugs than any other age 
group (60-63), and prescription of drugs is the most common form of medical treatment for 
older adults (64). 
1.4 DRUG USE IN OLDER PERSONS 
As a consequence of increasing longevity, people live longer with several diseases and are 
consequently treated with many drugs (65, 66). Drug treatment can reduce symptoms and 
morbidity, although there is a lack of evidence for treating frail older persons, as randomized 
clinical trials often exclude these patients (67, 68). 
Since elderly people often have multiple diseases and impairments (e.g. kidney failure, 
cognitive impairment), they are often sensitive to drugs. Still, polypharmacy (i.e. concurrent 
use of several drugs, often defined as use of ≥ 5drugs) (69) is common in old age (70-72). In 
Sweden, about 39% of community-dwelling and 76% of institutionalized people aged 65 
years and older have polypharmacy (66).  
Older persons are more likely than younger individuals to experience adverse drug reactions 
(73). These adverse events can lead to increased morbidity and mortality and also to 
increased costs for society (74-76). Indeed, it has been estimated that adverse drug events are 
involved in up to 30% of hospital admissions of older people (73). 
Previous research has shown that the most commonly used drugs in the elderly population in 
Sweden are antithrombotic agents, cardiovascular drugs, analgesics and psychotropic drugs 
(61, 66). These drug therapies largely reflect the co-morbidity burden among older persons 
(77). There are, however, differences in drug use depending on age, sex, socioeconomic 
position and residential setting (78, 79). In extreme old age, analgesics, hypnotics/sedatives 
and anxiolytics are common, whereas use of antidepressants is less common (60). Older 
women use more psychotropic drugs than older men, but less antithrombotic agents (80, 81). 
Older individuals with a higher educational level are more likely to use newly marketed drugs 
(82), but less likely to be exposed to polypharmacy (83), than individuals who have a lower 
level of education. Also, older people in institutions are more prone to use antidepressants, 
laxatives and analgesics than their community-dwelling counterparts (66, 84). 
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1.4.1 Altered pharmacokinetics and pharmacodynamics 
As a consequence of aging, the physical response to drugs is often altered (85). Physiological 
changes in the body can alter the drug effects in an undesirable way and prolong and/or 
increase the effect. The drug prescriber needs to be aware of these changes and balance the 
risk versus the benefits of the drug treatment (86).  
1.4.1.1 Pharmacokinetics 
Pharmacokinetics is often described as “what the body does to the drug”. It includes 
absorption, distribution, metabolism and excretion of the drug (87, 88). Absorption in itself is 
not age dependent, but surgery, some diseases and certain drugs (e.g. opioids and 
anticholinergic drugs) may delay absorption. The proportion of body fat increases in the 
aging body due to a reduction of the total volume of water. This results in a greater relative 
distribution volume of fat-soluble drugs, mainly centrally acting drugs, such as 
benzodiazepines, which may lead to prolonged effects. Drug metabolism is affected through a 
reduction of both blood flow and enzyme capacity in the liver (89). This may lead to 
increased drug concentrations, due to both increased bioavailability (i.e. the proportion of a 
given dose that reaches the bloodstream unchanged) and reduced metabolic clearance of the 
drug (90). This change can result in increased drug effects and adverse drug reactions (91, 
92). The most important age-dependent pharmacokinetic factor is, however, the renal 
excretion of drugs. Reduced renal function is common in old age, and as a consequence, 
accumulation of water soluble drugs may cause adverse drug reactions. Hence, it is crucial to 
measure renal function in older persons in order to adjust their drug treatment appropriately 
(93, 94). 
1.4.1.2 Pharmacodynamics 
Pharmacodynamics is often described as “what the drug does to the body” (87). Many organs 
and organ systems are altered with increasing age, mostly resulting in increased sensitivity to 
the effects of drugs. The brain becomes more sensitive to centrally acting drugs, which can 
cause excessive sedation, cognitive disturbances and falls (85, 95, 96). The baroreflex, which 
controls the blood pressure during, for example, postural changes, is often impaired in old 
age, leading to increased sensitivity to blood pressure lowering drugs (88). Furthermore, age-
related changes of the gastric mucosa increase the risk of gastrointestinal bleeding with 
certain drugs, mainly non-steroidal anti-inflammatory drugs (NSAIDs) and acetylsalicylic 
acid (97, 98). 
1.4.2 Drugs and dementia 
Due to pathological changes in the brain, people with dementia have a higher risk of adverse 
drug reactions when using central nervous system acting drugs (99-102). Yet, previous 
research has shown that persons with dementia often use psychotropic drugs and opioids 
(103-106). Prescription of these drugs can be problematic since they may cause cognitive 
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decline, falls and confusion (99, 107). Dementia patients are also sensitive to drugs with 
anticholinergic properties, which may negatively affect an already impaired cognition (108, 
109).  
Dementia often causes verbal difficulties which, in turn, can cause increased agitation and 
other behavioral symptoms when the affected individual is not able to communicate (110, 
111). Ultimately this may lead to overtreatment with psychotropic drugs (105, 112, 113). In 
contrast, the dementia diagnosis may dominate the clinical assessment, leading to 
undertreatment of somatic conditions (114, 115). However, few studies have assessed the 
quality of prescribing in people with dementia (116). 
Relatives and health care professionals may also have problems with identifying symptoms 
such as pain and depression in dementia (105, 117). This may lead to an undertreatment of, 
for example, depression, which has been reported to lead to morbidity and disability (118). 
On the other hand, a recent study shows that antidepressant use is three times more common 
in persons with AD than in persons without the disease (119), which may imply that the 
awareness and knowledge of depression in dementia have increased. 
Currently, there are four drugs that are approved for the symptomatic treatment of AD in 
Sweden. Three of these drugs are acetylcholine esterase inhibitors (donepezil, rivastigmine  
and galantamine) and the fourth drug (memantine) has effects on the glutamatergic system 
(46). The efficacy, clinical effectiveness and cost effectiveness of these drugs have been 
analysed in a comprehensive report by the Swedish Council on Health Technology 
Assessment (SBU – Statens beredning för medicinsk utvärdering) (120). They conclude that 
there is evidence that symptomatic treatment with acetylcholine esterase inhibitors have 
effects on cognitive performance for mild and moderate states of AD and that mematine has 
effects on moderate and severe states of AD.  
So far, there is no cure for AD or approved drugs that are labelled as disease modifying 
treatment (DMT) (47, 121). A DMT would not only have effects on symptoms but would 
also influence the underlying cause and the degeneration and death of neurons in AD. Many 
potential DMTs have been tested, but so far failed in phase III trials. However, there are still 
many such compounds in the pipeline (16, 122). Since there are great hopes that these drugs 
will result in decreased individual suffering and great cost savings, it is of great interest to 
analyse the potential cost effectiveness of DMT. Hence, we explored a hypothetical economic 
model of the cost effectiveness of DMT in AD in this thesis. 
1.4.3 Inappropriate drug use 
An important concept of drug therapy in old age is potentially inappropriate drug use (IDU), 
which has been defined in various ways in the literature. One common definition is “the use 
of medications for which the risks outweigh the benefits” (123-125). These drugs may be 
well tolerated in younger patients, but can, due to age-related changes, be regarded as 
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inappropriate among older patients. It is, however, important to note that treatment with these 
drugs may occasionally be justified for the individual patient (124, 126).  
Principally, the concept comprises the choice of drugs, the dosage and length of therapy, 
inappropriate combinations of drugs (drug duplication and drug-drug interactions (127)), 
drug-disease interactions and under-prescribing of drugs (128-130). Common examples of 
IDU are long-acting benzodiazepines, drugs with anticholinergic properties and drug 
combinations that may lead to serious drug-drug interactions (124).  
The prevalence of IDU has been reported to vary between 3 to 70 %, depending on the 
criteria used for defining IDU, the study populations and different settings (83, 123, 124, 131-
136). The highest prevalence of IDU is found in nursing homes where about 30% are 
exposed to IDU in Sweden (124, 137, 138).   
IDU is a well-recognized health problem in elderly persons and has been associated with 
adverse drug reactions, hospitalization, admission to nursing home and mortality (83, 116, 
133, 139-143). However, previous research about outcomes of IDU has often been limited by 
lack of information about important clinical variables, such as dementia, or by analysis of 
small and selected samples. Cost analysis of IDU has so far been scarce (144-146), although 
these estimations are important from a stakeholder and resource allocation perspective. 
Identifying IDU is of central importance in order to reduce the occurrence of drug-related 
problems in elderly patients. Therefore, several different criteria of IDU have been developed 
through expert consensus methods (134-136, 147), e.g. the Beers criteria from the US, the 
STOPP/START criteria from Ireland and the UK, the Laroche list from France and in 
Sweden a set of indicators developed by the National Board of Health and Welfare (128, 148-
150). Because availability of drug therapies, prescribing guidelines and therapeutic traditions 
vary between countries (136, 147, 151), use of national indicators of IDU, as in this thesis, 
may be beneficial, although they may prevent comparisons between countries.  
The Swedish indicators developed by the National Board of Health and Welfare include both 
disease- and drug specific indicators for evaluation of the quality of drug therapy in older 
people. The first version of the indicators was launched in 2003 and a revised version in 2010 
(126, 128). These indicators are quantitative measures based on international literature and 
expert consensus. Several of the drug-specific indicators have previously been used in 
pharmacoepidemiological studies (124, 152, 153), for example showing that risk factors for 
IDU are female gender (133), institutionalization (138) and multi-dose drug dispensing 
(dosexpedition, ‘Apodos’) (154). 
1.5 HEALTH ECONOMICS AND PHARMACOECONOMICS 
In any society, resources in a wide context are limited. Economics is the science dealing with 
how limited resources are handled and managed to address potentially unlimited needs. 
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Health economics is the application of economy within the medical, and wider, the social 
care sector (155).  
Any resource has an alternative use to which a certain cost for forgone benefits is attached.  
This cost is labelled as the opportunity cost which is recommended for use in economic 
evaluations (156). Although the opportunity cost concept may seem easy in theory where  
perfect market prices exists, it is not without problems when applying it to dementia, 
particularly regarding informal care (157, 158).  
According to Drummond et al (156), health economic evaluation studies can be classified as 
in Figure 3.  
 
Figure 3. Different kinds of health economic studies (adapted from Drummond et al (156)). 
In a cost effectiveness analysis (CEA), the consequences, or outcomes in terms of effects, are 
described in some kind of measurable physical units, such as survival, functional capacity or 
cognition. In a cost utility analysis (CUA), which may be regarded as a kind of CEA, the 
consequences are expressed in terms of utilities, such as quality adjusted life years (QALYs), 
see below. In a cost benefit analysis (CBA) both costs and consequences are monetary. In a 
cost minimization analysis (CMA), the consequences are assumed or shown to be similar 
and, thus, a cost analysis can be used. In this thesis, the application of health economics in 
terms of costs description (Study I, II, III) and cost effectiveness (Study IV) in dementia and 
drug use are explored. 
Pharmacoeconomics is the application of pharmacology in health economics (159). All 
pharmacoeconomic studies can be described according to the classification outlined in Figure 
3. Although use of drugs cannot be isolated from other aspects of care, pharmacoeconomics 
has a distinct focus on drugs, such as how large the costs of drugs are in relation to costs of 
other sectors of care (descriptive) or how cost effective drugs are (evaluations).  
Only costs Only outcomes
Both costs and 
outcomes
No comparator
Cost 
description
Outcome 
description
Cost outcome 
description
Cost 
effectiveness 
analysis (CEA)
Cost utility 
analysis (CUA)
Cost benefit 
analysis (CBA)
Cost analysis
Efficacy or 
effectiveness 
evaluation
Comparator
  
 
9 
1.5.1 Cost of illness 
Cost of illness (COI) studies are descriptive. Two approaches can be used: an incidence 
approach or a prevalence approach. With the incidence approach, the costs for new cases are 
estimated for both the annual costs and future (discounted) costs. In the approach, the costs 
for all cases during for example a year are estimated both for those who already have 
dementia as well as new cases occurring during the year under study (158, 160, 161).  
Instead of aggregated costs, as with the prevalence approach, the COI can also be presented 
as the cost per person with a disorder during a specified time period depending on the 
approach. COI per se cannot be used for setting priorities of specific care approaches. 
However, by highlighting the economic burden and by showing how costs change over time 
and are distributed between different payers, COI studies can in an indirect way indicate 
which diseases and disorders should be of interest for allocation of resources for research and 
care (23, 158, 162).   
1.5.2 Cost effectiveness 
A complete cost effectiveness analysis (CEA; CUA; CBA) should include both the analysis 
of costs and outcomes together with a comparison between at least two caring or treatment 
approaches. 
Cost effectiveness is often expressed as the Incremental cost effectiveness ratio (ICER): 
C/ E = (CA- CB)/ (EA - EB). 
Where C=costs, E=effects and A and B are different care or treatment options. 
The ICER expresses the ratio between the change in costs and the change in consequences, 
outcomes or effects for two or more interventions. 
A matrix for decision support is displayed in Figure 4. Cells 1 and 9 express complete 
dominance. For example in cell 1, the option A is both cheaper than B and has better effect. 
In cells 3 and 7, the ICER is particularly interesting since one option has better effect but at 
the same time is more expensive. In cell 5, either of the options can be chosen since both 
costs and effects are equivalent. 
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1.5.3 Health economic viewpoint 
Any economic evaluation must define its viewpoint. The viewpoint in this thesis is societal; 
thus aiming at reporting all included costs for society irrespective of payer. This approach 
may be regarded as the best option since it is possible to break down the costs into different 
payers. If, for example, only the payer of care is included in the analyses, the cost of informal 
care, which is a large cost in dementia, is neglected. This can be detrimental to the analyses 
(163, 164). 
1.5.4 Outcomes and effects 
The most frequently used utility concept in economic evaluations is Quality Adjusted Life 
Year (QALY) (165). QALYs are used in CUA and reflect both quantity and quality of life 
(166, 167). The key idea with QALYs is that this concept can be used for all kinds of 
diagnostic entities. Utilities are expressed as a figure with 0 representing death to 1 
representing perfect health. The basic idea is shown in Figure 5. One year of perfect health 
gains 1 QALY which is similar to three years with QALY values of 0.5+0.3+0.2 =1.0. 
 
 
Cost 
 
Effect 
 
A better 
than B 
A=B A worse than B 
A lower than B 1. Choose A 2. Choose A 3. ICER 
A=B 4 .Choose A 5. Neutral 
decision 
6. Choose B 
A higher than B 7. ICER 8. Choose B 9. Choose B 
Figure 4. Decision matrix for cost effectiveness analysis (adapted from 
Drummond et al.(156). 
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Figure 5. The basic idea of Quality Adjusted Life Years (QALYs).  
However, the use of QALYs is not uncontroversial (168). Chronic incurable progressive 
disorders may be disfavored when compared with surgical treatments, such as cataract 
surgery or hip replacement surgery (158).  
There are also other utility approaches, such as Disability Adjusted Life Years (DALYs) 
(169) which are used by the World Health Organization (WHO) and Healthy Years 
Equivalents (HYE) (170). However, DALYs focus on productivity and disability more than 
on quality of life and  HYEs require a great number of health scenarios (166). 
Diagnosis specific utilities are also under development to serve as equivalents or proxies for 
QALYs. The idea with such an approach is to provide greater possibilities of studying 
utilities of a disorder than the generic utility instruments can. Such diagnosis specific 
instruments in the field of dementia are presented in papers by Ekman et al (171) and the 
group working with DEMQOL-U (172). Even if they are more sensitive in detecting 
intervention effects than the generic instruments, the disadvantage is that comparisons with 
other disorders are difficult or even impossible. 
1.5.5 Long term effects 
The major challenge in the evaluation of dementia care, both in terms of clinical effectiveness 
and cost-effectiveness, is the long duration of dementia disorders. There is no single design 
that can solve this problem. Several approaches can be used, as displayed in Figure 6. The 
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term external validity refers to how generalizable results are in the population the study aims 
to describe, while internal validity refers to how well the study fulfills criteria for a controlled 
experiment or a trial.   
Most clinical studies last for 6-12 months while the progression and duration of for example 
AD may be several years to decades. Due to logistic and ethical issues, studies covering the 
whole disease period will probably never be accomplished. One option to determine long-
term effects is to extend ongoing studies and perform open follow-up studies (158). Such 
studies have been published on acetylcholinesterase inhibitors (173-175). However, there are 
several drawbacks with this approach, such as selection bias, patients lost to follow-up and 
problems in defining controls (158). Another interesting option is to analyse register data and 
to merge databases, e.g. record-linkage of national registers (176) with  quality registers (177) 
and population based studies, such as the Swedish National Study on Aging and Care 
(SNAC) (178). Another way of estimating long term effects, which has been used in this 
thesis (Study III and IV), is to use modelling techniques (179).  
 
Figure 6. Schematic view of external and internal validity in different types of studies 
1.5.6 Modelling/simulations 
There are several different modelling techniques for analysing long-term disease progression 
and the associated costs, but in general they are based on the same concept (180-182). This is 
made through short term input on efficacy or similar and, depending on the research question, 
input for progression, costs, outcomes and survival, which are extrapolated to a longer time 
period (a fixed period or expected survival). Because it is possible to use an input that reflects 
the situation of the target population, such as dementia, the representativity of the target 
External
validity
Models
Observational
studies
Registries
Naturalistic 
clinical trials
Randomized 
controlled trials
Laboratory 
experiments
Internal validity
  
 
13 
population, and thus the external validity, may be high. However, besides the empirical core 
of efficacy as input, the internal validity is low since long term effects are simulated.   
Frequently used modelling techniques are Markov models (183-185) (Study III and IV), 
decision trees, regression models, survival analysis and discrete event simulation (186). The 
basic concepts in a Markov cohort model (185) are states of a disease/disorder and transition 
probabilities between states and cycles (time, e.g. months, years).  
Figure 7 illustrates the basic idea of a Markov model. Transitions between states are 
illustrated with arrows and the corresponding transition probabilities (the probability to 
remain or change from one state to another), during one cycle (e.g. one year). Example: The 
probability to remain healthy is 0.80 while the probability of getting a disease or die is 0.18 
and 0.02, respectively (where 0.02 represents a risk of sudden death of a “healthy” person). 
The sum of transition probabilities for each state during one cycle are always 1.00 
(0.80+0.18+0.02).  
 
Figure 7. Principal overview of a Markov model 
A model is usually run for several cycles to illustrate the course of a condition. To each state, 
there are inputs regarding transition probabilities, costs, outcomes and several arms can be 
compared (such as treatment vs. no treatment), making it possible to calculate the ICER. The 
models are often presented in a tree-form. 
Since models have a rather long time horizon, the valuation of costs and consequences may 
differ. For example: if you have 1,000 SEK today and 1,000 SEK expected in 10 years, which 
option would you prefer? Probably the one of today. To adjust for these preferences over 
time, discounting is often used to give a future cost a present value (156). In short, 
discounting can be described as inverted interest rate calculations with a chosen discount rate. 
In the example above, with an annual discount rate of 3%, the present value of 1,000 SEK 10 
years later would be around 750 SEK.   
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1.5.7 Sensitivity analysis 
Any model consists of a set of input with an uncertainty for each input. Thus, the results of a 
model depend on the assumptions of the values of the different kinds of input. There are also 
different opinions about how to best estimate some of the input, e.g. costs of informal care 
(187, 188). Therefore, it is essential to test the robustness of a model by varying the different 
inputs (189).  
Depending on the type of input, different methods to test uncertainty need to be used, such as 
statistical variability (e.g. confidence intervals) and fixed alternative values (e.g. unit costs 
and discount rates). The sensitivity analysis can be a one way sensitivity analysis, where one 
input is varied at each occasion, or a probabilistic sensitivity analysis, where several kinds of 
input are varied simultaneously with several iterations and based on statistic variability of 
each input (such as standard deviations) (189). 
1.6 COSTS OF DEMENTIA 
The worldwide societal costs for dementia were estimated to be 604 billion US dollars in 
2010, of which 252 billion dollars in costs for informal care (17). These costs are expected to 
increase in the future because of population aging. It has even been questioned as to whether 
it will be possible to provide care and treatment for all persons with dementia in the future 
(190).  
In Sweden, the societal costs for dementia were estimated to be 63 billion SEK in 2012 (191). 
About 78%  of these costs occurred in the municipal sector, 17% in the informal care sector 
and only 5% occurred in the county council sector (191). The costs for the county councils 
refer to hospital care, primary care, diagnostic workup and costs for drug use. The costs of 
drugs only accounted for 2% of the societal costs(191). Consequently, the municipalities have 
undoubtedly the largest economic burden for the care of elderly people with dementia, but 
costs of drugs constitute a significant cost component for the county councils.  
Also internationally, the main cost drivers in dementia have been reported to be informal care 
and institutional care rather than medical care (i.e. inpatient and outpatient care and drugs) 
(164). Previous research has also shown that disease severity needs to be considered in 
studies of economic impact of dementia, as costs more than double from mild to severe states 
of the disease (192). 
However, longitudinal incidence-based COI studies of dementia are rare (193). Modelling 
approaches are useful in this context because of the long duration of dementia disorders that 
makes it difficult to collect empirical data (179).  
Studies of costs of dementia should clearly define cost components and separate estimates by 
care setting and disease severity to make them useful for health policy planning (164). Thus, 
we aimed to include all these aspects in this thesis. 
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1.7 THE CARE SYSTEM FOR OLDER PEOPLE IN SWEDEN   
In Sweden, about 90,000 elderly persons lived permanently in different kinds of institutional 
care and about 229,000 elderly persons received home help in 2013 (194).   
The responsibility for the care of older people in Sweden is shared between the 
municipalities and the county councils. In general, the municipalities have the responsibility 
of care in the social sector (day care, home-care, respite care and nursing homes), while the 
county councils are responsible for the primary care and the specialist medical care.  
However a transition process is taking place; care in the home, previously provided by 
nurses from primary care, is being taken on by the municipalities. 
 
Even if care is paid by these two main operators, care can also be organized by private 
companies using a care purchasing process (195). In 2012, 27% of the home help and 15% 
of the institutional care was carried out by private care providers in Sweden (196). 
Both in social care and in medical care, the care receiver pays fees. However, the greatest part 
is financed by taxes.  
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2 AIMS 
2.1 GENERAL AIM 
To investigate epidemiological and health economic aspects of dementia and drug use in 
older people, through economic modelling and analyses of population-based studies. 
2.1.1 Specific aims 
2.1.2 Study I 
To investigate whether dementia is associated with higher drug costs in older persons. 
2.1.3 Study II 
To investigate IDU and the risk of hospitalizations and mortality in older persons and in 
persons with dementia and to estimate the costs of IDU-related hospitalizations.  
2.1.4 Study III 
To describe the costs (including drug costs) of incident cases of dementia over time with a 
progression model based on Swedish conditions. 
2.1.5 Study IV 
To present a hypothetical economic model of the cost effectiveness of DMT in AD. 
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3 METHODS 
3.1 DATA SOURCES 
3.1.1 The Kungsholmen project (Study III and Study IV) 
The Kungsholmen project was a longitudinal population-based study conducted in the urban 
area of Kungsholmen in Stockholm during the years 1987-2000 (197). All persons aged 75 
years and older, including both institutionalized and community-dwelling persons, were 
invited and examined every third year (n=1,810 at baseline). Thorough medical and 
psychological examinations were performed as well as a structured interview by a trained 
nurse on health and social factors, including social network, education and functional status. 
Blood tests and measurements of physical performance were also gathered at every 
examination.  
In 1995, a rural node was included and then the project was called the Kungsholmen-
Nordanstig project (198, 199). Nordanstig is a municipality located in the county of 
Hälsingland, a coastal area in the middle part of Sweden. Nordanstig has no city or central 
area, only small villages. The same structured examination and test protocol were used in the 
rural area of Nordanstig as in the urban area of Kungsholmen.   
3.1.2 The Swedish National Study on Aging and Care (Study I and Study II) 
Building on the experiences from the Kungsholmen project, the Swedish National Study on 
Aging and Care (SNAC) was implemented in 2001 and is an ongoing longitudinal 
population-based multi-center study of aging and health conducted at four different sites in 
Sweden (178): the municipalities of Nordanstig and Karlskrona, four municipalities in the 
county of Skåne (Malmö, Eslöv, Hässleholm, Osby and Ystad) and 
Kungsholmen/Essingeöarna, a part of Stockholm city.  
In this thesis, baseline data from Nordanstig (SNAC-N) and Kungsholmen (SNAC-K) were 
used (n=4,129). Each consists of a sample of eleven age cohorts of the ages of 60, 66, 72, 78, 
81, 84, 87, 90, 93, 96 and 99 years and older. Baseline data were collected in 2001-2004. 
Persons over the age of 81 years are reexamined every third year and persons over the age of 
60 years every sixth year.  
The participants were examined extensively by using standardized protocols. The nurse’s 
interview covered a wide range of domains including socioeconomic status, living habits and 
family history. The participants were also examined by a physician, neuropsychological tests 
were performed by a psychologist and laboratory tests were collected. Data about diseases 
and drug use were collected during the interview with the physician. If a participant was 
unable to perform the interview, a proxy (spouse or next of kin) was asked instead. If the 
person lived in an institution, the information was most often collected from medical records 
and staff.  
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3.1.3 The National Patient Register (Study II) 
The National Patient Register (NPR) at the Swedish National Board of Health and Welfare 
was introduced in the 1960s and covers since 1987 all inpatient care in Sweden. The NPR 
contains, besides patient and medical data, also administrative and geographical data 
concerning every care episode. A validation of the NPR showed that over 99% of all                   
psychiatric and somatic discharges are recorded (200). 
3.1.4 The Cause of Death Register (Study II) 
The Cause of Death Register at the Swedish National Board of Health and Welfare contains 
since 1961 data on all deceased persons registered as inhabitants in Sweden at the time of 
death. The register is updated annually and causes of death are coded according to 
international ICD codes (201). 
3.2 MODELLING APPROACHES (STUDY III AND STUDY IV) 
For the modelling approaches, many different sources of information formed the base for the 
models. This composite was collected both from epidemiological studies (i.e. the 
Kungsholmen project) as well as from demographic statistics and registers. Markov models 
were used to simulate the cohorts in Study III and Study IV (185).  
There is currently no cure for AD. Consequently, there are no available empirical figures of 
efficacy or cost-effectiveness of this kind of treatment. In Study IV, a hypothetical DMT was 
assumed to lower the risk of progression from MCI to more severe forms of dementia, also 
affecting the subsequent progression in later states.  
3.2.1 Clinical Dementia Rating (Study III) 
Clinical Dementia Rating (CDR) (202) was used to describe dementia severity.  The states 1, 
2 and 3 were translated into mild, moderate and severe dementia. Study III used only states 1, 
2 and 3. CDR state 0.5, rather similar to MCI, was not included in the model. The 
Kungsholmen project of people aged 75 years and older were used as empirical foundation 
(197, 199). 
3.2.2 Mini Mental State Examination (Study IV) 
In Study IV, states and progression of dementia in the model were defined by Mini Mental 
State Examination (MMSE) (203). MMSE is a screening instrument used for assessing 
cognitive impairment and can also be used as a tool for assessment of dementia severity.  The 
scoring is 0-30, where a low score indicates worse cognitive impairment. A widely used 
stratification of MMSE scoring is: mild (18-23), moderate (10-17) and severe (0-9) cognitive 
impairment (204).  
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3.2.3 Resource Utilization in Dementia (Study III and Study IV) 
Severity state specific costs were derived from the Kungsholmen project (205, 206) and were 
based on the Resource Utilization in Dementia (RUD) instrument (207, 208). RUD is a 
comprehensive instrument used to assess the resource utilization in dementia and aims at 
calculating costs from a societal viewpoint, also including costs of informal care (Table 1).  
Table 1. Components of the RUD instrument (209) 
 
Patient Caregiver 
Accommodation/long term care Caregiver time (for patient) 
Respite care Work status 
Hospital care Hospital care 
Out patient visits Out patient visits 
Social service Social service 
Home nursing care Home nursing care 
Day care Day care 
Drug use Drug use 
Work status 
 
For each resource, there is a unit cost applied and the resulting cost is based on the 
multiplication of the quantity of the resource and the unit cost, considering the time window.  
3.3 OUTCOME VARIABLES AND EXPLANATORY VARIABLES 
3.3.1 Outcome variables 
3.3.1.1 Drug use (Study I and Study II) 
Use of drugs was recorded by the physician through personal interviews and the participants were 
asked to bring current lists of medications, drug containers and prescriptions. If the participant 
was not able to answer, a proxy (spouse or next-of-kin) was asked to provide the information. 
Drug use was defined as use of a drug regularly at the time of the interview or as needed at any 
time during the preceding month. Data on both prescribed and over the counter (OTC) drugs were 
recorded. The drugs were classified according to the Anatomical Therapeutic Chemical 
(ATC) code, as recommended by the WHO (210).  
3.3.1.2 Drug costs (Study I) 
Drug costs were calculated based on a register of drug prices from the National Corporation 
of Swedish Pharmacies (Apoteket AB) from 2003, in a specialized computer software 
(Monitor
©
). Every drug used by each participant was sought out in the drug register. 
Thereafter, a matching preparation and strength was looked up and a suitable package was 
selected. For tablets or capsules, packages with 100 or close to 100 tablets/capsules were 
selected. For other preparations, such as mixtures, the largest package was selected. The price 
of the package was divided by the number of tablets, capsules or number of ml in cases of 
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fluid drugs. The price per unit was then multiplied with the number of units taken daily by the 
participant. For drugs taken as needed, we instead calculated the price per Defined Daily 
Dose (DDD), which is the average daily dose of a drug when used for its main indication in 
an average 70 kg adult, as established by WHO (210), and we assumed that drugs used as 
needed were taken in an average dose of half a DDD per day. For anti-infective drugs, we 
assumed a limited treatment period of 20 days per year. 
3.3.1.3 Hospitalization (Study II) 
The hospitalization data used in Study II were collected from the NPR. The data was 
collected from the time point of entrance of the participant into the study until one year after. 
Both acute and planned hospitalizations were included.  
3.3.1.4 Costs of hospitalization (Study II) 
To obtain the cost of the hospitalizations we used the ICD codes from the NPR. The ICD 
codes were translated into Nord-Diagnose Related Group (DRG) codes, which are a Swedish 
version of the original DRG codes (211, 212). The Nord-DRG database was developed to 
rationalize cost-finding and budgeting for practitioners. A DRG code has a specific weight 
and this weight was multiplied with the DRG cost of weight 1 to get a total cost for the actual 
hospital stay.  For example, renal failure has DRG code 316 and in the year 2003 it had a 
weight of 1.2558 and the cost of 1 DRG was 43,661 SEK, resulting in a cost for the hospital 
visit of about 55,000 SEK. 
3.3.1.5 Mortality (Study II) 
Death certificates were retrieved from the national Cause of Death Register, from the date of 
inclusion of the participant until one year after.  
3.3.1.6 QALYs (Study IV) 
In study III, QALYs were used as outcome variable showing the effect of the hypothetical 
treatment for the simulated cohort. QALYs were accumulated for the cohort throughout the 
modelled period and allocated to the treated persons in the cohort. 
3.3.2 Explanatory variables  
3.3.2.1 Sociodemographic variables  
Sociodemographic data covered age, gender, educational level and residential setting.  
In the descriptive analysis, age was divided into age groups of 60-69, 70-79, 80-89 and 90 
years and over, whereas in the regression models age was included as a continuous variable. 
Educational level was dichotomized into eight years or less (elementary) and nine years or 
more of schooling (additional). Residential setting was used as a dichotomous variable: living 
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in own home (community-dwelling) vs. living in an institution. Institutional living referred to 
all forms of sheltered housing, e.g. service-house, group-living and nursing homes.  
3.3.2.2 Comorbidity 
We used the Charlson comorbidity index (213), which is widely used to control for 
confounding effects of concurrent diseases. The index has been validated for both 
administrative databases (214) and institutional living (215, 216). We used an adapted 
version (139) based on the availability of data. The index consisted of nine diagnoses 
(weighted as below) resulting in the total sum of 11: myocardial infarction, congestive heart 
failure, cerebrovascular disease, dementia, chronic obstructive pulmonary disease, connective 
tissue disease, diabetes without complication, moderate or severe renal failure and any 
tumour. Moderate or severe renal disease and a diagnosis of tumour had the weight of two 
and all other diseases the weight of one. All diagnoses were based on information available in 
medical records and from the physician’s examination, except for dementia and renal disease. 
The dementia diagnosis was made by the physician according to the DSM III-R criteria (217) 
and renal disease was estimated through calculations using the of Cockcroft-Gault formula 
(218). An estimated creatinine clearance <25mL/min was assumed to indicate severe renal 
disease. 
3.3.2.3 Physical functioning 
We used the Katz ADL index as a measure of daily functioning (219). The Katz index is a 
hierarchical scale that measures physical dependence in six different basic daily activities; 
bathing, dressing, going to the toilet, transferring, continence and feeding. The level of 
dependency was expressed in grades from 0 to 6 with zero representing being totally 
independent in all of the activities and 6 being dependent in all six activities. Good 
reliability and construct validity have been reported for the Katz index when administered 
by nurses (220), which is done in both the Kungsholmen project and in the SNAC study.  
3.3.2.4 Dementia status 
The dementia diagnosis was made according to the DSM III-R (217), based on information 
obtained from patient history, medical examination and cognitive testing. If the participant 
was unable to answer questions, information was retrieved from a proxy, most often a spouse 
or next-of-kin. If the person lived in an institution, the information was most often collected 
from medical records and staff.  
3.3.2.5 Inappropriate drug use (IDU) 
The Swedish National Board of Health and Welfare has developed indicators for the 
evaluation of the quality of drug therapy in elderly people (128). These indicators are 
quantitative measures based on international literature and expert consensus. The indicators 
are divided into drug specific and disease specific. In this thesis (Study II), we used four of 
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the drug specific indicators (Table 2), which have previously been used in studies of IDU 
(124, 133, 138). 
 
Table 2. Indicators developed by the Swedish National Board of Health and Welfare for 
analyses of IDU in elderly persons (Study II)* 
Indicator 
Examples of drug /drug 
combinations 
May cause (examples) 
Anticholinergic drugs Antihistamines, urinary 
antispasmodics, low-potency 
antipsychotics 
Cognitive impairment, 
confusion and impaired 
functional status  
Long-acting 
benzodiazepines  
Diazepam, nitrazepam, 
flunitrazepam 
Excessive sedation, 
cognitive impairment and 
falls  
Concurrent use of three 
or more psychotropic 
drugs 
Antipsychotics, anxiolytics, 
hypnotics-sedatives and 
antidepressants 
Excessive sedation, 
cognitive impairment and 
falls  
Potentially serious drug-
drug interactions  
Concurrent use of aspirin and 
warfarin  
Attenuated/abolished 
therapeutic effects or 
severe side effects  
*Adapted from Haasum 
(221).   
 
 
3.4 STATISTICAL ANALYSIS  
3.4.1 Statistical analysis (Study I and Study II) 
Descriptive demographic statistics were made with cross-tabulations in both Study I and 
Study II. Cost data is often non-normally distributed with a skewed distribution. Accordingly, 
in Study I, the regression analysis of costs was performed by using a Generalized Linear 
Model (GLM) with the assumption of a gamma shaped distribution of the dependent variable 
(222). GLMs are generally well suited for statistical analysis of cost data, which often show a 
high degree of non-normality (223).  
In Study I, a two-step procedure was adopted. Firstly, logistic regression with costs as binary 
outcome was performed in order to observe which factors were associated with high costs. 
Secondly, a GLM model was run to explore the magnitude of the cost-driving factors. In the 
GLM, the major cost drivers were dichotomized and first entered separately. All models were 
adjusted for age, gender and education. Then, all factors were entered in the joint analysis 
simultaneously. Dementia diagnosis is included in the Charlson Comorbidity Index, but in the 
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joint analysis, dementia was analysed as a separate variable and, thus, was removed from the 
index.  
In Study II, we used logistic regression analysis to explore the association between IDU and 
hospitalizations within one year from assessment of IDU, after adjustment for covariates. We 
used Cox regression models for analysis of IDU and mortality within one year from 
assessment of IDU, after adjustment for covariates. Firstly, the outcomes of hospitalizations 
and mortality were analysed in the whole population. Secondly, we analysed the 
subpopulation of persons with dementia. The results are shown as odds ratios (ORs) and 
hazard ratios (HRs) with 95% confidence intervals (95% CIs). We used one way analysis of 
variance (ANOVA) to explore differences in mean cost of hospitalizations with and without 
IDU, after adjustment for age. 
Inclusion of site (i.e. Kungsholmen and Nordanstig) did not affect the main results; therefore, 
this variable was not included in the analyses. A p-value of < 0.05 was considered statistically 
significant in both Study I and Study II.  
All analyses in Study I and Study II were made with IBM SPSS Statistics version 22 (224).  
3.4.2 Transition probabilities (Study III and Study IV) 
Markov models were used to simulate the cohorts in Study III and Study IV. These models 
are based on the probability to make a transition between two or more states/events. The 
probability of transition between states of dementia, from mild to moderate and severe, was 
considered in the models. The transition probabilities between states also included mortality 
figures for mild, moderate and severe states of dementia. They were derived from the 
Kungsholmen project (197, 225). In both Study III and Study IV, there were no possibilities 
of back transition implicating that the progression of the disease was irreversible in the 
model.  
3.4.3 Sensitivity analysis (Study III and Study IV) 
In all modelling approaches, it is essential to test the model variation and robustness in order 
to investigate if the assumptions are reasonable. In a one-way sensitivity analysis, the 
mortality, transition probabilities between states, costs of informal care, discount rates and 
incidences were varied in the models. 
In Study IV, additional sensitivity analysis of the hypothetical DMT on conversion rate to 
AD and proportion of responders of the treatment were varied. In addition, the cost of the 
hypothetical treatment and the possibility to enrich the target population through including 
persons with MCI-AD detected by using biomarkers was varied. 
All analyses in Study III and Study IV were performed by using the software Treeage (226) 
and the extended analyses was performed in Microsoft Excel (227).
  
 
25 
4 ETHICAL CONSIDERATIONS 
4.1 KUNGSHOLMEN PROJECT AND SNAC 
Study III and Study IV used data from the Kungsholmen project approved by the ethical 
board in Stockholm (Dnr: 94:122; 87:148; 87:234; 90:251). Study I and Study II used 
baseline data from the SNAC study conducted in Nordanstig and Kungsholmen which was 
approved by the ethical review boards in Stockholm (Dnr 01-114) and Uppsala (Dnr 01-123).  
Both studies collected informed consent from each participant and if not possible, proxy 
consent was requested from a close relative. The Kungsholmen and SNAC projects follow 
the ethical guidelines of the Swedish Council for Research in the Humanities and Social 
Sciences. 
4.2 REGISTER DATA 
Study I and Study II used data from the National Patient Register and the Cause of Death 
Register record-linked to baseline data from SNAC-K and SNAC-N, which  was approved by 
the ethical review boards of Stockholm (Dnr 01-114, dnr 2009/595-32) and Uppsala (dnr 01-
123). The register data were made anonymous prior to merging with the SNAC data and only 
non-identifiable data were analysed.
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5 MAIN RESULTS 
5.1 STUDY I 
In Study I, drug use data and the associated costs were analysed for people with and without 
dementia. Of the 4,129 participants, 21 did not have information on drug use and were 
therefore excluded from the analyses (n=4,108; 319 with dementia). 
The mean age for people without dementia was 73.2 (SD 10.6) years and for people with 
dementia 88.1 (SD 7.2) years. Community-dwelling participants had a mean age of 73.9 (SD 
10.6) years and participants in institutions 88.6 (SD 7.5) years. 
About 80% of all participants used drugs. The mean number of drugs was 5.4 in people with 
dementia and 3.5 in people without dementia (p<0.001). The mean number of drugs used 
among community-dwelling persons was 3.4 and in institutions 6.3 (p<0.001). 
The overall annual drug costs for persons with and without dementia were 6,147 SEK and 
3,810 SEK, respectively. Cardiovascular drugs (ATC group C), nervous system drugs (ATC 
group N) and drugs for the alimentary tract and metabolism (ATC group A) accounted for the 
majority of the drug costs; 55% in individuals without and 73% in individuals with dementia. 
The cost of nervous system drugs was more than five times higher in persons with dementia 
than without (3,202 SEK vs 585 SEK). This was explained by the higher use of virtually all 
types of nervous system drugs, including analgesics, antiepileptics, psychotropics and anti-
dementia drugs, among the persons with dementia. Cardiovascular drugs were also more 
common among persons with dementia, but to a lower mean cost than among persons without 
the disease (514 SEK among persons with dementia and 1,009 SEK among persons without 
dementia). This was explained by the high use of high-ceiling diuretics, nitrates and cardiac 
glycosides among the individuals with dementia, whereas individuals without dementia had a 
higher use of beta blocking agents, calcium channel blockers, angiotensin II antagonists and 
lipid modifying agents. 
The results of the GLM analysis revealed that, after adjustment for comorbidities and 
residential setting, dementia was not associated with higher overall drug costs. When the total 
costs of drugs were stratified by dementia status and residential setting, people living in 
institutions and without a diagnosis of dementia accounted for the highest costs of drugs 
(Figure 8).  
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Figure 8. Total cost of annual drug use stratified by dementia status and residential setting. 
The strongest drug cost driver was comorbidity followed by residential setting. 
Thus, the GLM showed that after adjustment for age, gender, residential setting, physical 
functioning, comorbidity and dementia, the main drug cost drivers for elderly people are 
comorbidities and residential setting and not dementia per se. 
5.2 STUDY II 
In Study II, we analysed IDU – defined as exposure to at least one of four drug specific 
indicators according to the set developed by the Swedish National Board of Health and 
Welfare (Table 3) (138), and the risk of hospitalization and mortality in older persons and in 
persons with dementia. Of the 4,129 participants, 21 did not have information on drug use 
and were therefore excluded from the analyses (n=4,108; 319 with dementia). 
The mean age of the study population was 74.8 years ranging from 60 to 105 years. Overall 
prevalence of IDU was 13%; 27% among persons with dementia and 12% among persons 
without dementia (p<0.001). The prevalence of IDU in institutions was 34% and among 
community-dwellers 12% (p<0.001). 
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IDU was associated with a higher risk of hospitalization within one year in the whole study 
population (adjusted OR=1.46; 95% CI 1.18-1.81), after adjustment for age, sex, dementia, 
residential setting, educational level, physical functioning and comorbidity (Table 3).  
 
Table 3. Multivariate logistic regression analysis of the association between 
inappropriate drug use (IDU) and hospitalization within one year
a
 
 
 OR* (95% CI) 
Age, years (cont.) 1.04 (1.03, 1.05) 
   
Sex   
  Male Reference  
  Female 0.80 (0.67, 0.92) 
   
Dementia   
  No Reference  
  Yes 0.97 (0.68, 1.39) 
   
Residential setting   
  Community-dwelling Reference  
  Institution 0.25 (0.16, 0.38) 
   
Education   
  Elementary Reference  
  Additional 0.72 (0.61, 0.86) 
   
Katz ADL   
  Independent Reference  
  Dependent 2.15 (1.58, 2.92) 
   
Co-morbidity   
  No co-morbidities Reference  
  Co-morbidities 1.35 (1.15, 1.58) 
   
IDU   
  No Reference  
  Yes 1.46 (1.18, 1.81) 
      
a
 Data missing for 52 persons 
* Adjusted for all variables in table 
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IDU was also associated with mortality within one year (adjusted HR=1.15; 95% CI 1.01, 
1.31), after adjustment for age, sex, dementia, residential setting, educational level, physical 
functioning, comorbidity and hospitalization within 1 year (Table 4).  
 
Table 4. Multivariate Cox proportional hazard regression analysis for 
inappropriate drug use (IDU) and risk of mortality within one year
a
 
 
 HR* (95% CI) 
Age, years (cont.) 1.07 (1.06, 1.08) 
   
Sex   
  Male Reference  
  Female 0.76 (0.68, 0.84) 
   
Dementia   
  No Reference  
  Yes 1.28 (1.08, 1.52) 
   
Residential setting   
  Community-dwelling Reference  
  Institution 1.09 (0.90, 1.52) 
   
Education   
  Elementary Reference  
  Additional 0.93 (0.83, 1.03) 
   
Katz ADL   
  Independent Reference  
  Dependent 1.18 (1.01, 1.39) 
   
Co-morbidity   
  No co-morbidities Reference  
  Co-morbidities 1.41 (1.27, 1.56) 
   
Hospitalization within 1 year   
  No Reference  
  Yes 1.37 (1.23, 1.53) 
   
IDU   
  No Reference  
  Yes 1.15 (1.01, 1.31) 
                    a
 Data missing for 52 persons 
       * Adjusted for all variables in table 
 
We also performed the analyses only among the persons without dementia. However, the 
results of these analyses were similar to that of the whole study population. 
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Among the persons with dementia, IDU was associated with a higher risk of hospitalization 
within one year (adjusted OR=1.88; 95% CI 1.03-3.43), but not statistically significantly 
associated with mortality (adjusted HR=1.13; 95% CI 0.87-1.47).  
Costs for hospitalizations, estimated based on data from the NordDRG, seemed higher in 
persons with IDU than without IDU, although not statistically significant (Figure 9).  
 
 
Figure 9. Costs of hospitalization in people with and without inappropriate drug use (IDU) 
stratified by dementia status 
5.3 STUDY III 
By conducting a 10-year simulation of a cohort of incident cases of dementia, we aimed to 
estimate the long term costs of dementia. Figure 10 shows the model used in Study III.  
According to our calculations, we estimated approximately 24,000 incident cases of dementia 
in Sweden 2005. The simulation was run for 10 cycles of one year each. After three years in 
the base model, the simulated cohort had been reduced to only 45% of the original 24,000 
incident cases due to mortality.  
In total, the 10-year cost for the simulated cohort was about 27 billion SEK. Institutional care 
was the main cost driver and accounted for 51% to 91% of the total costs from year 1 to year 
10. Total costs of drugs in dementia only accounted for about 2% of the costs in the model.  
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Figure 10.  Base model for the incident dementia cohort 
The states of mild and moderate dementia generated costs of about 12 billion SEK during the 
modelled period, constituting a proportion of almost 44% of the total costs. The severe state 
of the disease generated about 56% of the total costs, even though only about a third of the 
duration of the disease was spent with severe dementia. Thus, the severe state of dementia 
accounted for the largest proportion of costs for incident dementia cases. 
By far, the highest costs were the costs of institutionalization, even as early as year 1 (Figure 
11). Institutionalization accounted for 96% of the total costs in the case of the severe state and 
for 37% in the mild state of disease. 
 
 
Figure 11. Total costs of incident dementia cohort stratified by type of cost. 
When costs of informal care were varied in the sensitivity analysis from cost of leisure time 
of 91 SEK/hour to a replacement cost of 350 SEK/hour reflecting the change to a 
professional carer, the total cost increased with 27%. When testing different scenarios of 
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mortality, the option of high end 95% mortality confidence interval showed 26% decrease in 
total costs. 
5.4 STUDY IV 
In Study IV, a simulation was conducted in a Markov model of a hypothetical DMT aiming 
at treating MCI and mild states of dementia.  
The simulation of DMT resulted in no societal cost savings when exploring the base case 
scenario for the whole cohort. In the base case, the incremental cost per person was 239,061 
SEK. The higher cost was the result of the treatment itself and the fact that treated persons 
lived longer. The difference in survival was 0.9 years in favor of treated persons (Figure 12).  
 
Figure 12. Survival curve of the model period 
In terms of effect, the treated persons gained 0.82 QALYs and the resulting ICER was 
293,000 SEK per gained QALY. 
The sensitivity analysis showed that only one option was cost neutral and that was when the 
cost of the DMT was at the same level as for the acetylcholinesterase inhibitors (before these 
drugs became generic) and when the treatment did not affect mortality. With the assumption 
that DMT would have an effect, in all scenarios, the QALYs of the treated group exceeded 
the untreated group. If adopting a societal level of WTP of 600,000 SEK, all options of the 
treatment, except if cost for treatment was 300,000 SEK or more per annum, would be 
considered cost effective. A PSA was made with 1,000 iterations where distributions of 
transitions between states of AD and mortality and conversion to dementia were varied. The 
PSA (Figure 13) showed that in 99% of the simulations, the treatment option was in favour of 
DMT when adopting the above mentioned WTP, as shown in Figure 13. 
 
 
  
 
33 
 
 
 
  
Figure 13. PSA Scatterplot of DMT treatment vs no treatment 
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6 DISCUSSION 
6.1 MAIN FINDINGS 
This thesis explored epidemiological and health economic aspects of dementia and drug use 
through analyses of population-based studies and economic modelling with a multi-
disciplinary approach (228). As people live longer lives, many will suffer from age-related 
disorders, such as dementia, and many will use several drugs for their multiple conditions. 
These are major challenges for the society.  
Drug use is extensive among older persons (66, 229). Indeed, about 80% of the older persons 
were found to use at least one drug (Study I). Drug treatment has its own costs (Study I) but 
there are also consequences of drug use in terms of IDU and adverse events (Study II), which 
are rarely given any economic value in COI and cost effectiveness studies. Costs of drug 
treatment in the elderly population is, as shown in this thesis, rather high and is expected to 
increase with the aging of the population (230). 
If costs of hospitalization due to IDU (Study II) are added to the cost of the drugs, the total 
cost of drug treatment has a great impact on any health care budget (231). Thus, IDU may not 
only cause personal suffering and an increase in mortality (Study II) from suboptimal drug 
treatment, but also seems to led to great expenditures for society (232).  
The difference in hospitalization costs between people with and without IDU for the whole 
study population in Study II was around 3,700 SEK (although not statistically significant). If 
it is assumed that this gap is still valid in 2013 and the proportion of IDU patients is the same 
in the whole of Sweden (13%) for people aged 60 years and older, the aggregated extra 
hospitalization costs of IDU would amount to 1.2 billion SEK in 2013 ((18,718 SEK-15,045 
SEK)* 2,444,102 (people 60+) *0,13). This figure is in line with a recent report by Fastbom 
(233), where the cost of hospitalizations due to adverse drug events among elderly people 
was estimated to be 900 million SEK.  
However, not all costs related to IDU are avoidable. IDU may be a consequence of a 
necessary medical decision or part of a calculated risk where expected benefits were judged 
as greater than the estimated risks. 
Costs of elderly care are extensive and particularly the cost of dementia care. In 2012, the 
societal costs of dementia in Sweden were estimated to be 63 billion SEK per annum (191). 
A wide economic approach can provide answers as to how societal resources may be 
allocated and give best value for money. Costs and effects can be measured and reported 
from different viewpoints. The viewpoint in this thesis is societal; thus aiming at reporting all 
included costs for society including informal care costs (Study III and Study IV). 
To be able to give correct estimates of societal costs (Study III) and cost effectiveness of 
treatment (Study IV) in a broader sense, regarding a disorder such as dementia, it is crucial to 
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have input from population-based studies where non-users of care are included. If clinical or 
convenience study populations are used as input, there is a risk of overestimating the costs 
Dementia generates costs in a complex manner and several payers are involved. These 
different payers are also involved at different time points in the course of the disease. There 
are transitions from care at home with informal family support in the early states, to long term 
care in the late state of dementia. When a modelling study (like Study III and IV) is 
performed, the sensitivity analysis is of great importance in order to show the robustness of 
the model. Inferences drawn from any health economic study rely on the validity of the many 
different kinds of input and since health economic studies are often a composite of different 
sources, evaluation of the different sources is even more crucial (234, 235).   
6.2 THE IMPACT OF DEMENTIA ON DRUG COSTS 
Economic studies of drug use in the elderly population have often focused on costs or cost-
effectiveness of a single drug (236-241). Few previous studies have analysed both the 
magnitude of drug use at the level of drug classes and its costs. There is an extensive use of 
drugs among older persons and the associated drug costs are also high. We are, to our 
knowledge, among the first to compare costs for people with and without dementia in a 
population-based study, after adjustment for background factors in a regression model.   
People with dementia used more drugs (5.4) than people without dementia (3.5) (Study I). 
Also the overall annual crude drug costs were higher for persons with than without dementia 
(6147 SEK vs. 3810 SEK). Moreover, the cost of nervous system drugs was more than five 
times higher in persons with dementia than without. Persons with dementia who are living in 
nursing homes often use psychotropic drugs (103, 242, 243), even though they are more 
likely to experience side effects of these drugs (99-102). However, there are now encouraging 
signs of a decline in the prescribing of these drugs to elderly persons (153, 244).  
The cost for anti-dementia drugs was at the time frame of Study I very high and, thus, 
influenced the costs of nervous system drugs to a great extent. However, the prescription of 
these drugs was not very high at that time point (12% among persons with dementia). Today, 
the use of anti-dementia drugs is higher but the cost of these drugs is considerably lower. 
Since the patents have expired, costs for anti-dementia drugs have decreased to only about 
5% of the cost at the time of Study I.  
Costs for cardiovascular drugs were lower in the dementia group, even though the use was 
more frequent than among persons without dementia (Study I). These results are in 
concordance with previous findings showing that institutionalized elderly persons (of whom 
many have dementia or cognitive impairment) are less likely to use more expensive 
cardiovascular drugs (66). Persons with dementia were also older and their cardiovascular 
drug treatment may have been initiated a long time ago and then continued, although new and 
more expensive cardiovascular drugs were introduced on the market (60). 
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Drug costs in old age should be expected to be high given that elderly people often have 
many comorbid conditions (245-247). When comparing our results with a previous Swedish 
study (248), the costs for drug use had increased much more in the dementia group than in the 
group without dementia. This was partly explained by the introduction of the acetylcholine 
esterase inhibitors, but also by distinctly higher use of antidepressants, opioids and 
antipsychotics in the dementia group.  
In the regression model, with adjustment for background factors, we found that the higher 
crude drug cost in persons with dementia was confounded by residential setting and 
comorbidities. One explanation for this confounding phenomenon could be that persons with 
dementia often live in nursing homes where use of drugs acting on the central nervous system 
is extensive (103, 242, 243). 
6.3 INAPPROPRIATE DRUG USE IN OLDER PEOPLE AND IN PERSONS WITH 
DEMENTIA 
IDU is common among older persons (91). We found an overall prevalence of IDU of 13% 
(Study II), which is lower than found in previous studies from the UK and Ireland (145, 249, 
250), but similar to findings from Swedish national data (138).  
We found that IDU was more common among persons with dementia and among persons in 
institutional care (Study II). These findings are in agreement with previous research from 
Sweden (131, 138, 251). Thus, IDU is most common among the frailest older people, which 
warrants more caution in prescribing to this vulnerable group of patients. 
IDU was also found to be associated with an increased risk of both hospitalization and 
mortality, after adjustment for sociodemographic, functional and comorbidity factors. Hence, 
our study gives support to the growing body of literature on the negative outcomes of IDU 
and supports restrictive prescribing of these drugs in elderly patients (116, 124, 137, 139-141, 
147, 252-255).  
Moreover, we found a tendency for higher costs for hospitalizations with IDU than without 
IDU, although not statistically significant (Study II). Hospitalizations are likely to be the most 
costly outcome of IDU and may be, at least partly, preventable by more appropriate 
prescribing to older persons (144). The gap between hospital care costs for people with and 
without IDU in dementia was around 1,200 SEK. If this cost difference (although not 
statistically significant) is extrapolated to the whole Swedish dementia population, it 
represents a cost of about 185 million SEK per year. These costs could be added to the 
societal costs for dementia in COI estimates. 
The results on IDU in this thesis show the importance of monitoring and reviewing drug 
therapy of elderly people both with and without dementia. Since the time of the baseline data 
collection in the SNAC-project, there has been a major focus on IDU in older people in 
Sweden and there are now encouraging findings of an improved quality of drug prescribing to 
this patient group (153). 
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6.4 COSTS OF DEMENTIA 
Dementia is a long-term progressive disease and subsequently accounts for substantial 
societal costs (17), besides the burden of the disease itself for the affected persons and their 
families (256, 257). The long-term progressive nature of dementia disorders also entails a 
problem to collect all cost data during the course of the disease. In Sweden, the municipalities 
are faced with the majority of these costs while the county councils are responsible for a 
smaller share of the societal costs (258).  
Study III shows that the highest costs for dementia occur in severe dementia and that long-
term institutional care is the major cost driver, even in mild dementia. Even though many 
persons with dementia live at home, the costs of institutional care are so high that its 
proportion of the total costs for dementia is substantial. These findings are in line with recent 
findings from several European countries and may have implications for resource allocation 
and for strategies of long-term care placement (259-261).  
Even though drug costs only accounted for 2% of the costs of dementia in Study III, its 
impact on the health care sector is high (191). 
6.5 COSTS OF DISEASE MODIFYING TREATMENT AND PREVENTION IN 
DEMENTIA 
The valuation of a DMT (Study IV), both in forms of efficacy and costs, is a hazardous task 
given that there is currently no such compound available on the market. Many trials so far 
have shown no efficacy or have been affected by safety issues (16).  
Besides the disease modifying track, there are also great hopes of preventing AD through 
modifiable risk factors with up to as much 60% (262). The most influential risk factors 
identified today are the vascular risk factors (e.g. physical inactivity, smoking and midlife 
hypertension, obesity and diabetes) and depression (263-267). Interventions aimed at lifestyle 
factors have so far reported mixed results (268). One study focusing on prevention has also 
undergone complete health economic evaluation, i.e. of cost- effectiveness in a modelling 
approach, which showed that people in the intervention group gained QALYs and that the 
intervention cost less than usual care (269).   
When, and if, a curable treatment for dementia enters the market, diagnosing the disease at an 
early stage may be necessary in order to change the course of the disease. New diagnostic 
criteria for AD have been suggested in this respect (270-273). However, the ethical 
implications concerning possible erroneous AD diagnoses are very important to consider.   
According to our results (Study IV), developing a DMT for dementia will not lead to any 
cost-savings, mainly because of the prolonged survival with dementia and the cost of DMT. 
However, given that the societal WTP level is not exceeded, DMT could be considered cost 
effective. Even though our study showed no cost savings, a DMT can generate improved 
quality of life for the patient in gained QALYs. The higher cost for society is a consequence 
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of the treatment cost itself and the fact that it affects mortality. Hence, the prolongation of life 
with dementia will generate more costs to society. However, studies on this topic are rare. In 
a study without cost-effectiveness estimates, it was shown that time in long-term care was 
reduced and survival was prolonged with DMT (274).  
6.6 LIMITATIONS 
A general limitation of cross-sectional data is that no causal inference can be drawn. 
Simulation studies based on Markov models (Study III and IV) come with a set of limitations. 
A general limitation is the hypothetical nature of all simulations, i.e. a set of input values, 
taken from a fixed period of time, is used to calculate future scenarios. More specific to this 
thesis, dementia progression may alter with age, comorbid conditions and aggressiveness of 
the disease. Dementia is often associated with concurrent diseases and these diseases have 
their own costs, which we have not included (275, 276). 
Other simulation techniques than those used in this thesis are available, such as discrete event 
simulation (DES) (277), but the most important aspect of any modelling approach is that the 
underlying assumptions are well-founded. When using hypothetical assumptions, as in Study 
IV, transparency is essential.  
Our modelling approaches were based on Swedish conditions and may therefore have limited 
generalizability to countries with other care systems. We also used data from people aged ≥75 
years (Study III and IV), which constitutes about 82% of the dementia population (205). Cost 
of informal care is controversial and often discussed (187, 188). Therefore, the informal care 
cost was varied in the sensitivity analysis to reflect different cost scenarios like the 
replacement cost and opportunity cost. Simulations can like other studies be biased and as a 
result potentially report incorrect numbers (278). For example, when a set of transition 
probabilities is estimated to be the same from mild dementia to moderate dementia as from 
moderate dementia to severe dementia, while in real life the transition probability of 
switching from mild to moderate dementia is lower than the probability of progressing from 
moderate to severe dementia (278), bias is introduced in the model.  
6.6.1 Selection bias 
An epidemiological study always runs the risk of selection bias. This is the case when 
distortions in the exposure-outcome association occur that is related to the procedure of 
selecting participants to a study and from factors related to study participation (279).  
However, both the Kungsholmen project and the SNAC study are in this respect well 
designed (178, 197). The participation rates were high in both studies with only small 
differences in the distribution of age, gender and education between participants and non-
participants. Further, both the Kungsholmen project and the SNAC study include both 
community-dwelling and institutionalized persons, and proxy interviews when needed. This 
reduces the risk for systematic health differences between the participants and non-
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participants (280). Thus, it is reasonable to think of the study population as representative of 
the source population. 
6.6.2 Misclassification of outcome variables 
Misclassification occurs when the collected information about an individual or group is 
erroneous. Both information on outcomes and exposures can be misclassified. It is important 
to consider whether the misclassifications are systematic or not. Non-systematic (non-
differential) misclassification will, in most cases, lead to an attenuation of associations. 
However, systematic (differential) misclassification can lead to spurious associations (279). 
6.6.2.1 Drug use and drug costs 
There are several ways of collecting drug data, e.g. through interviews, using register data 
from pharmacies and medical records. Self-reported data, as used in this thesis, runs the risk 
of recall bias. Comparisons between self-reported data and other sources of drug use data 
have shown plausible under-reporting for self-reported data (281-283). However, unlike 
register data from pharmacies, which provide information about filled prescriptions, 
interview data also include information about OTC drugs and drugs that are actually taken 
and not only purchased.  
Costs for the collected drug use are prone to the same risk of misclassification since the cost 
data are based on calculations from the underlying drug data. In the context of this thesis, the 
largest limitation would be if drug use and costs were systematically misclassified between 
persons with and without dementia. However, given the use of proxy interviews and that a 
trained physician was responsible for recording the drug use; the risk of systematic 
misclassification should be limited. 
6.6.2.2 Hospitalization 
All data on hospitalization were derived from the NPR. Validity of the data is high for almost 
all diagnoses (200). Misclassification is possible through diagnostic errors, translation errors 
and coding errors, but in total the errors are reported to be at a very low level (200). 
6.6.2.3 Cost of hospitalization 
When translating the ICD code of the NPR to costs derived from the Nord-DRG database, all 
of the above mentioned hospitalization errors can occur. Furthermore, the risk of erroneous 
underlying ICD codes may occur.   
6.6.3 Misclassification of explanatory variables 
Comorbidity was assessed by the Charlson comorbidity index (213) and included nine 
different diseases (i.e. myocardial infarction, congestive heart failure, cerebrovascular 
disease, dementia, chronic pulmonary disease, connective tissue disease, diabetes, renal 
failure and any tumour). However, the Charlson comorbidity index may not have completely 
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reflected the comorbidity burden among the participants. Further, there would have been a 
greater risk of bias if the index had relied on self-reported data only. Therefore, data on the 
diseases were collected through structured interviews by a physician, a clinical examination 
and blood testing.  
Physical functioning was assessed by the Katz index of ADL (219) through interviews with 
trained nurses. If the participant was unable to answer, a next of kin was interviewed instead. 
It has previously been shown that assessments in a structured interview give higher validity 
than self-reported data (284). However, we cannot be certain that physical functioning has 
been completely accounted for in the analyses, given that this measure is difficult to estimate 
(285). 
6.6.4 Confounding 
In all pharmacoepidemiological studies, there is a risk of confounding by indication. This 
means that the association between drug use and outcomes can be confounded by the 
underlying disease that the drug is indicated for (286). We have tried to handle this in Study I 
and II by including a co-morbidity index (139) and hospitalization within one year as a proxy 
for disease severity in Study II (139).  
Furthermore, we also took into account major known confounders in our data, such as age, 
sex, education, residential setting and physical functioning. However, residual confounding 
due to unknown factors cannot be excluded. 
6.7 CONCLUSIONS 
This thesis aimed at investigating dementia and use of drugs through analyses of population-
based studies and economic modelling in a multi-disciplinary context. 
The findings about drug therapy in persons with and without dementia revealed that the 
higher overall crude drug costs in dementia were confounded by comorbidities and residential 
setting. However, cost of nervous system drugs was more than five times higher in persons 
with dementia than without. Persons with dementia also used cardiovascular drugs to a higher 
extent but at a lower cost, indicating an older type of cardiovascular drug treatment in 
dementia patients. These findings may reflect differences in underlying disease patterns or 
differences in the care of persons with and without dementia. 
We also found that IDU was associated with an increased risk of hospitalization and mortality 
among older persons. IDU might also lead to higher costs for society, although this needs to 
be investigated in further studies. This underlines the need for caution in the prescribing of 
these drugs to elderly patients. A large share of IDU is possible to avoid, which would benefit 
both society and elderly patients (233). 
Our findings on net costs in dementia showed that the highest accumulated costs occur in 
severe dementia and that the major cost driver is institutionalization, even in mild dementia. 
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Drugs, on the other hand, constitute only a minor part of the total costs. It is essential to be 
transparent about all assumptions in a simulation model since costs are sensitive to 
assumptions concerning e.g. informal care, progression and mortality in dementia. 
Finally, we found that DMT in dementia is projected to not be cost saving if the treatment 
prolongs survival. Still, if a societal willingness-to pay level of 600,000 SEK is adopted, the 
treatment can be considered cost effective. However, DMT would include very long 
treatment periods at high costs and with risks of adverse events. 
6.8 FUTURE DIRECTIONS 
Drug use in older people is a highly topical and timely research area. The implementation of 
the individual-based Swedish Prescribed Drug Register in 2005 provided new possibilities for 
advanced large-scale pharmacoepidemiological studies (287), including analyses of drug 
therapy in the elderly population. However, register data does not reveal all the information 
about an individual’s drug treatment. On the other hand, older people may have more 
difficulties with self-reporting their complete drug use due to cognitive decline and 
polypharmacy. Therefore, validation studies of self-reported drugs vs. data from the Swedish 
Prescribed Drug Register are needed to disentangle the pros and cons of these different data 
sources among older persons.  
Record linkage of population-based studies to register data is a valuable method for creating 
datasets that are rich in both clinical and self-reported variables as well as in objective and 
detailed data. This type of record-linkage is already done, but could be extended to also 
include the Swedish quality registers (e.g. the Swedish Dementia Registry). 
There is also a need for longitudinal pharmacoepidemiological studies to provide valuable 
information about causal relationships and about changes in drug use over time.  
The differences in drug treatment between persons with and without dementia merit further 
investigation. Future studies should aim to disentangle whether these differences reflect 
biomedical differences or if drug prescription is also affected by other factors such as 
communication problems and oversight of somatic conditions in persons with dementia.  
The costs of IDU-related hospitalizations seemed high in this thesis. Further studies are 
needed to confirm our results and to assess to what extent these hospitalizations are avoidable 
through educational interventions and more cautious prescribing.  
After the data for this thesis were collected, new treatment guidelines have been 
implemented, new drugs have reached the market and patents have expired. Therefore, the 
studies conducted within this thesis should be updated in order to investigate current 
conditions.  
Simulations are well suited for describing long term progressive diseases and their associated 
costs. We have done analyses and projections based on Swedish data and our results may 
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mainly be applicable to our nearest neighbors (i.e. the Nordic countries). Hence, it would be 
of great interest to do the same kind of analyses in other countries or even globally in order to 
explore how costs are distributed in different health care systems with different payers. The 
hardest obstacle might be to find comparable and appropriate data sources.  
Finally, it would be interesting to apply the same modelling techniques to other long term and 
progressive disorders like Parkinson’s disease. There are also other interesting and suitable 
modelling techniques (e.g. discrete event simulation) that may have benefits when simulating 
diseases with long time perspectives and this has not yet been done under Swedish 
conditions. 
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